Proteomics and liver fibrosis: identifying markers of fibrogenesis

References

• Friedman SL. Liver fibrosis – from bench to bedside. J. Hepatol.38, S38–S53 (2003).
   PubMed Web of Science ®Google Scholar
• Schuppan D, Ruehl M, Somasundaram R, Hahn EH. Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis.21, 351–372 (2001).
   PubMed Web of Science ®Google Scholar
• Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem. J.411(1), 1–18 (2008).
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int.28(8), 1052–1064 (2008).
   PubMed Web of Science ®Google Scholar
• Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut57(2), 268–278 (2008).
   PubMed Web of Science ®Google Scholar
• Henderson NC, Forbes SJ. Hepatic fibrogenesis: from within and outwith. Toxicology254(3), 130–135 (2008).
   PubMed Web of Science ®Google Scholar
• Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol. Res.58(2), 129–136 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic fibrosis – overview. Toxicology254(3), 120–129 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology134(6), 1655–1669 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman SL, Bansal MB. Reversal of hepatic fibrosis – fact or fantasy? Hepatology43(2 Suppl. 1), S82–S88 (2006).
   PubMed Web of Science ®Google Scholar
• Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm. Res.25(2), 249–258 (2008).
   PubMed Web of Science ®Google Scholar
• Guo J, Friedman SL. Hepatic fibrogenesis. Semin. Liver Dis.27(4), 413–426 (2007).
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest.115(2), 209–218 (2005).
   PubMed Web of Science ®Google Scholar
• Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev. Gastroenterol. Hepatol.2(6), 803–816 (2008).
   PubMedGoogle Scholar
• Rockey DC. Antifibrotic therapy in chronic liver disease. Clin. Gastroenterol. Hepatol.3(2), 95–107 (2005).
   PubMed Web of Science ®Google Scholar
• Said A, Lucey MR. Liver transplantation: an update 2008. Curr. Opin. Gastroenterol.24(3), 339–345 (2008).
   PubMed Web of Science ®Google Scholar
• Renz JF, Kin C, Kinkhabwala M et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann. Surg.242(4), 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• Brown RS, Rush SH, Rosen HR et al. Liver and intestine transplantation. Am. J. Transplant.4(Suppl. 9), 81–92 (2004).
   PubMed Web of Science ®Google Scholar
• Zachary D. Goodman. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol.47(4), 598–607 (2007).
   PubMed Web of Science ®Google Scholar
• Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol. Clin. Biol.32(6 Suppl 1), 52–57 (2008).
   PubMedGoogle Scholar
• Murtagh J, Foerster V. Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis. Issues Emerg. Health Technol.90, 1–4 (2006).
   Google Scholar
• Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J. Gastroenterol.15(20), 2433–2440 (2009).
   PubMed Web of Science ®Google Scholar
• Sawyers CL. The cancer biomarker problem. Nature452(7187), 548–552 (2008).
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature452(7187), 564–570 (2008).
   PubMed Web of Science ®Google Scholar
• Neusser MA, Lindenmeyer MT, Kretzler M, Cohen CD. Genomic analysis in nephrology – towards systems biology and systematic medicine? Nephrol. Ther.4(5), 306–311 (2008).
   PubMed Web of Science ®Google Scholar
• Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol.7(14), 1948–1960 (2007).
   PubMed Web of Science ®Google Scholar
• Walters KA, Katze MG. Using high-throughput genomics to study hepatitis C: what determines the outcome of infection? Antiviral Res.81(3), 198–208 (2009).
   PubMed Web of Science ®Google Scholar
• Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int.26(9), 1021–1028 (2006).
   PubMed Web of Science ®Google Scholar
• Mas VR, Fisher RA, Archer KJ et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation83(7), 973–981 (2007).
   PubMed Web of Science ®Google Scholar
• Mas VR, Maluf DG, Archer KJ et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol. Med.15(3–4), 85–94 (2009).
   PubMed Web of Science ®Google Scholar
• Lederer SL, Walters KA, Proll S et al. Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. Virol. J.3, 98–108 (2006).
   PubMedGoogle Scholar
• Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin. Liver Dis.29(2), 188–199 (2009).
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J. Clin. Gastroenterol.36(3), 242–252 (2003).
   PubMed Web of Science ®Google Scholar
• Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin. Exp. Res.30(4), 709–719 (2006).
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H et al. Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene22(19), 3007–3014 (2003).
   PubMed Web of Science ®Google Scholar
• Song EJ, Babar SM, Oh E, Hasan MN, Hong HM, Yoo YS. CE at the omics level: towards systems biology--an update. Electrophoresis29(1), 129–142 (2008).
   PubMed Web of Science ®Google Scholar
• Diamond DL, Jacobs JM, Paeper B et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology46(3), 649–657 (2007).
   PubMed Web of Science ®Google Scholar
• Mölleken C, Sitek B, Henkel C et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology49(4), 1257–1266 (2009).
   PubMed Web of Science ®Google Scholar
• Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics4(12), 3665–3685 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics6(1), 4–8 (2006).
   PubMed Web of Science ®Google Scholar
• Tonge R, Shaw J, Middleton B et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics1(3), 377–396 (2001).
   PubMed Web of Science ®Google Scholar
• Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis18(11), 2071–2077 (1997).
   PubMed Web of Science ®Google Scholar
• Domon B, Aebersold R. Mass spectrometry and protein analysis. Science312(5771), 212–217 (2006).
   PubMed Web of Science ®Google Scholar
• Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem.18, 2071–2077 (2001).
   Google Scholar
• Veenstra TD. Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.847(1), 3–11 (2007).
   PubMed Web of Science ®Google Scholar
• Hu L, Ye M, Jiang X, Feng S, Zou H. Advances in hyphenated analytical techniques for shotgun proteome and peptidome analysis--a review. Anal. Chim. Acta598(2), 193–204 (2007).
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal. Chem.75(7), 148A–155A (2003).
   PubMed Web of Science ®Google Scholar
• Joos T, Bachmann J. Protein microarrays: potentials and limitations. Front. Biosci.4, 4376–4385 (2009).
   Google Scholar
• Kopf E, Zharhary D. Antibody arrays – an emerging tool in cancer proteomics. 39(7–8), 1305–1317 (2007).
   Google Scholar
• Cheung KJ, Tilleman K, Deforce D, Colle, Van Vlierberghe H. Proteomics in liver fibrosis is more than meets the eye. Eur. J. Gastroenterol. Hepatol.20(5), 450–464 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Diamond DL, Chan EY et al. Proteome analysis of liver cells expressing full-length hepatitis C virus replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. J. Virol.79(12), 7556–7569 (2005).
   Google Scholar
• Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics4(12), 3960–3974 (2004).
   PubMed Web of Science ®Google Scholar
• Kristensen DB, Kawada N, Imamura K et al. Proteome analysis of rat hepatic stellate cells. Hepatology32(2), 268–277 (2000).
   PubMed Web of Science ®Google Scholar
• Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology43(2 Suppl. 1), S113–S120 (2006).
   PubMed Web of Science ®Google Scholar
• Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am. J. Gastroenterol.100(9), 1981–1983 (2005).
   PubMed Web of Science ®Google Scholar
• Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol.29(12), 1705–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology128(2), 343–350 (2005).
   PubMed Web of Science ®Google Scholar
• Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology41, 48–54 (2005).
   PubMed Web of Science ®Google Scholar
• White IR, Patel K, Symonds WT et al. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J. Transl. Med.5, 33 (2007).
   PubMedGoogle Scholar
• Poynard T, Morra R, Ingiliz P et al. Biomarkers of liver fibrosis. Adv. Clin. Chem.46, 131–160 (2008).
   PubMed Web of Science ®Google Scholar
• Ngo Y, Munteanu M, Messous D et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem.52(10), 1887–1896 (2006).
   PubMed Web of Science ®Google Scholar
• Poon TC, Hui AY, Chan HL et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study.Clin. Chem.51(2), 328–335 (2005).
   PubMed Web of Science ®Google Scholar
• Sun S, Lee NP, Poon RT et al. Oncoproteomics of hepatocellular carcinoma: from cancer markers’ discovery to functional pathways. Liver Int.27(8), 1021–1038 (2007).
   PubMed Web of Science ®Google Scholar
• Santamaría E, Muñoz J, Fernández-Irigoyen J, Prìeto J, Corrales FJ. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int.27(20), 163–173 (2007).
   PubMed Web of Science ®Google Scholar
• Sun W, Zhong F, Zhi L, Zhou G, He F. Systematic -omics analysis of HBV-associated liver diseases.Cancer Lett. DOI:10.1016/j.canlet.2008.12.002 (2009) (Epub ahead of print).
   Google Scholar
• Ward DG, Cheng Y, N’Kontchou G et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br. J. Cancer94(2), 287–292 (2006).
   PubMed Web of Science ®Google Scholar
• Ward DG, Cheng Y, N’Kontchou G et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br. J. Cancer95(10), 1379–1383 (2006).
   PubMed Web of Science ®Google Scholar
• Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation87(1), 143–152 (2009).
   PubMed Web of Science ®Google Scholar
• American Liver Tumor Study Group. A randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigators Booklet and protocol 1998. United Network for Organ Sharing. Policy 3.6.4.4.1998.
   Google Scholar
• Cui J, Kang X, Dai Z et al. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J. Cancer Res. Clin. Oncol.133(11), 825–834 (2007).
   PubMed Web of Science ®Google Scholar
• He QY, Zhu R, Lei T et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J. Cell. Biochem.103(3), 740–752 (2008).
   PubMed Web of Science ®Google Scholar
• Wallace JC, Korth MJ, Diamond DL, Proll SC, Katze MG. Virology in the 21st century: finding function with functional genomics. Future Virol.1, 47–53 (2006).
   Web of Science ®Google Scholar
• Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology43(Suppl.), S145–S150 (2006).
   PubMed Web of Science ®Google Scholar
• Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology126, 1795–1808 (2004).
   PubMed Web of Science ®Google Scholar
• Asselah T, Bièche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin. Liver Dis.27(1), 13–27 (2007).
   PubMed Web of Science ®Google Scholar
• Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem.52, 1815–1817 (2006).
   PubMed Web of Science ®Google Scholar
• Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell. Biol.36, 598–606 (2004).
   PubMed Web of Science ®Google Scholar
• Kubota A, Okamura S, Omori F et al. High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. Clin. Lab. Haematol.17, 61–63 (1995).
   PubMedGoogle Scholar
• Tacke F, Gäbele E, Bataille F et al. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig. Dis. Sci.52, 3404–3415 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn J, Prante C, Schön S, Götting C, Kleesiek K. Measurement of fibrosis marker xylosyltransferase I activity by HPLC electrospray ionization tandem mass spectrometry. Clin Chem.52, 2243–2249 (2006).
   PubMed Web of Science ®Google Scholar